Pfizer reups PPD deal in a contract research pact spree

Pfizer building
(Tracy Staton)

Pfizer has always been a heavy user of CROs, and over the past few months it’s been ramping up its partnerships.

Last month, it doubled down on its existing pact with Syneos Health (the results of the INC Research and inVentiv Health merger in 2018), a few months after signing a similar deal with Icon; now it’s doing the same with PPD.

The U.S. Big Pharma and the CRO have signed up to a new three-year agreement to “provide drug development services to advance Pfizer’s portfolio”, the pair said in a brief update. According to the deal, Pfizer can also boost this pact for an additional two years.

Virtual Roundtable

ESMO Post Show: Highlights From the Virtual Conference

Cancer experts and pharma execs will break down the headline-making data from ESMO, sharing their insights and analysis around the conference’s most closely watched studies. This discussion will examine how groundbreaking research unveiled over the weekend will change clinical practice and prime drugs for key new indications, and panelists will fill you in on the need-to-know takeaways from oncology’s hottest fields.

RELATED: Pfizer signs up for longer pact with Icon, pens extra 2-year clause

Pfizer picked PPD as one of its “preferred” CROs back in 2015. Financial terms were not made public, as is usually the case with these deals.

“United in purpose, we are committed to building on our long-standing relationship with Pfizer with innovative solutions, quality execution and the dedication of our talented teams to help Pfizer deliver exciting new therapies,” said David Simmons, PPD’s chairman and CEO.

“PPD is strategically positioned to continue supporting Pfizer in its pursuit of breakthroughs that change patients’ lives. We are privileged to take the next steps together and contribute to Pfizer’s initiatives to achieve a healthier world.”

Suggested Articles

Novartis is forging ahead with the development of spartalizumab in "many, many other indications" despite the setback.

Chi-Med has detailed plans to seek approval from the FDA later this year in part on the strength of data from Chinese phase 3 trial.

Takeda tapped Roche’s Foundation Medicine to develop tissue- and blood-based companion diagnostic tests for its portfolio of lung cancer therapies.